BiotechTube
Isomorphic Labs

Isomorphic Labs

London, United Kingdom· Est.
isomorphiclabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $600M

Overview

Isomorphic Labs is a private, AI-native drug discovery company spun out from DeepMind, leveraging its foundational AlphaFold technology. The company has developed a proprietary 'Drug Design Engine' capable of generating drug candidates for challenging targets across small molecules, antibodies, peptides, and molecular glues. It has entered a significant, multi-target research collaboration with Johnson & Johnson, signaling validation of its platform and a shift towards pipeline development. Led by AI pioneer Demis Hassabis and a team of seasoned drug discovery and machine learning experts, Isomorphic is positioned as a leading player in the emerging field of digital biology.

AI / Machine Learning

Technology Platform

A multi-modality AI Drug Design Engine built on AlphaFold technology, capable of generating and optimizing drug candidates (small molecules, antibodies, peptides, molecular glues) for challenging biological targets.

Funding History

2
Total raised:$600M
Public Offering$600M
SeedUndisclosed

Opportunities

The company has the opportunity to fundamentally reshape the inefficient drug discovery process by applying its powerful, multi-modality AI platform.
Strategic partnerships with major pharmaceutical firms provide validation, non-dilutive funding, and a path to the clinic.
Backing by Alphabet provides unparalleled resources and stability for long-term, ambitious research.

Risk Factors

The core technology is unproven in delivering clinical-stage assets, representing significant technical and translational risk.
The competitive landscape for AI drug discovery is intense and rapidly evolving.
The partnership-centric business model limits control and economic upside compared to developing a proprietary pipeline.

Competitive Landscape

Isomorphic competes in the rapidly growing AI-driven drug discovery sector against public companies like Exscientia, Recursion Pharmaceuticals, and Insilico Medicine, as well as numerous private startups and internal initiatives at large pharma. Its primary competitive advantages are its direct lineage from the groundbreaking AlphaFold system, its multi-modality platform, and the immense financial and technical backing of Alphabet.

More companies in AI / Machine Learning →More companies in United Kingdom →